Cargando…

Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands

This study aims to assess how clinical outcomes of immunotherapy in real-world (effectiveness) correspond to outcomes in clinical trials (efficacy) and to look into factors that might explain an efficacy-effectiveness (EE) gap. All patients diagnosed with stage IV non-small cell lung cancer (NSCLC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cramer-van der Welle, Christine M., Verschueren, Marjon V., Tonn, Merel, Peters, Bas J. M., Schramel, Franz M. N. H., Klungel, Olaf H., Groen, Harry J. M., van de Garde, Ewoudt M. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973789/ https://www.ncbi.nlm.nih.gov/pubmed/33737641 http://dx.doi.org/10.1038/s41598-021-85696-3

Ejemplares similares

Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
por: Cramer-van der Welle, Christine M., et al.
Publicado: (2018)

The association between gut microbiome affecting concomitant medication and the effectiveness of immunotherapy in patients with stage IV NSCLC
por: Verschueren, M. V., et al.
Publicado: (2021)

Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014
por: Cramer-van der Welle, Christine M., et al.
Publicado: (2020)

Real‐world treatment patterns and outcomes of patients with extensive disease small cell lung cancer
por: Cramer‐van der Welle, Christine M., et al.
Publicado: (2020)

Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
por: Mfumbilwa, Zakile A., et al.
Publicado: (2023)

Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands
por: Reesink, Daan J., et al.
Publicado: (2020)

Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC
por: Ismail, R. K., et al.
Publicado: (2023)

Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC
por: Ismail, R. K., et al.
Publicado: (2023)

Cost-effectiveness of screening smokers and ex-smokers for lung cancer in the Netherlands in different age groups
por: Al Khayat, Mohamed N. M. T., et al.
Publicado: (2022)

The dynamics in applied COVID-19 pharmacotherapy and the influence of national guidance in The Netherlands: a quantitative and qualitative study
por: Uitvlugt, Elien B, et al.
Publicado: (2022)

‘Care for Outcomes’: systematic development of a set of outcome indicators to improve patient-relevant outcomes for patients with lung cancer
por: Cramer-van der Welle, Christine M, et al.
Publicado: (2021)

Consecutive antibiotic use in the outpatient setting: an extensive, longitudinal descriptive analysis of antibiotic dispensing data in the Netherlands
por: de Jong, Loek A. W., et al.
Publicado: (2019)

Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer
por: Révész, Dóra, et al.
Publicado: (2019)

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
por: Noordhof, Anneloes L., et al.
Publicado: (2023)

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands
por: Verduyn, S Cora, et al.
Publicado: (2012)

Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non–Small-Cell Lung Cancer in the Netherlands
por: Wolff, Henri B., et al.
Publicado: (2022)

The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review
por: Vis, Roeland, et al.
Publicado: (2020)

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
por: Wachters, F M, et al.
Publicado: (2005)

GMP-compliant (68)Ga radiolabelling in a conventional small-scale radiopharmacy: a feasible approach for routine clinical use
por: Vis, Roeland, et al.
Publicado: (2015)

Antibiotic prescribing on admission to patients with pneumonia and prior outpatient antibiotic treatment: a cohort study on clinical outcome
por: van de Garde, Ewoudt M W, et al.
Publicado: (2015)

Comparison of norovirus genogroup I, II and IV seroprevalence among children in the Netherlands, 1963, 1983 and 2006
por: van Beek, Janko, et al.
Publicado: (2016)

CYP3A4 inhibitors do not influence [(68)Ga]Ga-DOTA-TATE uptake in liver tissue
por: Chahid, Youssef, et al.
Publicado: (2023)

Pharmacogenomic insights into treatment and management of statin-induced myopathy
por: Peters, Bas JM, et al.
Publicado: (2009)

Compliance to DMD Care Considerations in the Netherlands
por: Heutinck, Lotte, et al.
Publicado: (2021)

Risk factors for nonvisualization of the sentinel lymph node on lymphoscintigraphy in breast cancer patients
por: Chahid, Youssef, et al.
Publicado: (2021)

Motives for reporting adverse drug reactions by patient-reporters in the Netherlands
por: van Hunsel, Florence, et al.
Publicado: (2010)

The Influence of Long-Acting Somatostatin Analogs on (68)Ga-DOTATATE Uptake in Patients With Neuroendocrine Tumors
por: Chahid, Youssef, et al.
Publicado: (2023)

Phase IV non-inferiority trials and additional claims of benefit
por: Bernabe, Rosemarie DLC, et al.
Publicado: (2013)

Prioritizing Emerging Zoonoses in The Netherlands
por: Havelaar, Arie H., et al.
Publicado: (2010)

Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials
por: van den Hoek, Hester L, et al.
Publicado: (2011)

The detection of monkeypox virus DNA in wastewater samples in the Netherlands
por: de Jonge, Eline F., et al.
Publicado: (2022)

Improving guideline adherence for cardiac rehabilitation in the Netherlands
por: Kemps, H. M. C., et al.
Publicado: (2011)

Impact of severe necrotizing fasciitis on quality of life in the Netherlands
por: van Stigt, Sander F. L., et al.
Publicado: (2022)

Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands
por: Broers, Merel C., et al.
Publicado: (2022)

Listeria monocytogenes meningitis in the Netherlands, 1985–2014: A nationwide surveillance study
por: Koopmans, Merel M., et al.
Publicado: (2017)

Treatment of patients with rare bleeding disorders in the Netherlands: Real‐life data from the RBiN study
por: Maas, Dominique P. M. S. M., et al.
Publicado: (2022)

Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial
por: Brouns, Anita J. W. M., et al.
Publicado: (2020)

Disease burden of neonatal invasive Group B Streptococcus infection in the Netherlands
por: de Gier, Brechje, et al.
Publicado: (2019)

Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy
por: Bui, Tam Binh V, et al.
Publicado: (2019)

Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations
por: Willemsen, Annelieke E. C. A. B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t2or2bkbds9ob7trjki2m1tjvn